The company will commercialize their ecobody system” developed by Professor Hideo NAKANO. From singularized B-cells obtained from a trace amount of blood, mAbs can be produced in a cell-free E. coli system, and mAbs with high affinity and high selectivity for a target antigen are selected using recombinant E. coli. The whole process takes only 2 days.”

Nikkei Biotech news release, May 16, 2018